



**ONCONOVA**  
THERAPEUTICS

## **Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference**

Sep 06, 2023

NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25<sup>th</sup> Annual Global Investment Conference being held September 11-13, 2023.

### **Presentation Details**

Date/Time: Monday, September 11, 2023, available on-line beginning at 7:00 AM ET

Speaker: Steven Fruchtman, M.D., President & CEO

Investor Access: [Webcast Link](#)

1X1 meetings The Onconova Management Team will be available for 1X1 meetings during the conference. Those interested in requesting a meeting should contact their H.C. Wainwright representative.

The presentation can be viewed [here](#) or on the "[Corporate Events and Presentations](#)" section of the Onconova website and will be archived for 90 days.

### **About Onconova Therapeutics, Inc.**

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company's product candidates include proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova's novel, proprietary multi-kinase inhibitor narazaciclub (formerly ON 123300) is being evaluated in a Phase 1/2 combination trial with the estrogen blocker, letrozole, in advanced endometrial cancer ([NCT05705505](#)). Based on preclinical and clinical studies of CDK 4/6 inhibitors, Onconova is also evaluating opportunities for combination studies with narazaciclub and letrozole in additional indications.

Onconova's product candidate rigosertib is being studied in multiple investigator-sponsored studies, including a dose-escalation and expansion Phase 1/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer ([NCT04263090](#)), a Phase 2 program evaluating oral or IV rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC ([NCT03786237](#), [NCT04177498](#)), and a Phase 2 trial evaluating rigosertib in combination with pembrolizumab in patients with metastatic melanoma ([NCT05764395](#)).

For more information, please visit [www.onconova.com](http://www.onconova.com).

### **Company Contact:**

Mark Guerin  
Onconova Therapeutics, Inc.  
267-759-3680  
[ir@onconova.us](mailto:ir@onconova.us)  
<https://www.onconova.com/contact/>

### **Investor Contact:**

Bruce Mackle  
LifeSci Advisors, LLC  
646-889-1200  
[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)